ArticleCancer medicine2023
Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Risk factors for return to work in workers who experienced cancer: a systematic review with meta-analysis.Oncology reviews · 2026Pooled it
- Factors associated with employment outcomes in cancer survivors: a systematic scoping review spanning a decade of international research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Factors Associated With Employment and Quality of Working Life in Patients With Metastatic Breast Cancer.Cancer medicine · 2025Article
- Personal Factors Associated with Satisfaction in Labor Market Participation Among Cancer Survivors.Journal of rehabilitation · 2025Article
- Return to work in younger patients with brain metastases who survived for 2 years or more.Journal of neuro-oncology · 2025Article
- Brain metastasis, secondary to breast cancer, and strategies for improving quality of life.The British journal of occupational therapy · 2024Article
- Contemporary vocational rehabilitation strategies for people with advanced cancer: A literature review and conceptual framework.Journal of vocational rehabilitation · 2024Article
- Planning for return to work during the first year after breast cancer metastasis: A Swedish cohort study.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlanning for return to work (RTW) is relevant among sub-groups of metastatic breast cancer (mBC) survivors. RTW and protective factors for RTW in patients with mBC were determined.
methodsPatients with mBC, ages 18-63 years, were identified in Swedish registers, and data were collected starting 1 year before their mBC diagnosis. The prevalence of working net days (WNDs) (>90 and >180) during the year after mBC diagnosis (y1) was determined. Factors associated with RTW were assessed using regression analysis. The impact of contemporary oncological treatment of mBC on RTW and 5-year mBC-specific survival was compared between those diagnosed in 1997-2002 and 2003-2011.
resultsOf 490 patients, 239 (48.8%) and 189 (36.8%) had >90 and >180 WNDs, respectively, during y1. Adjusted odds ratios (AORs) of WNDs >90 or >180 during y1 were significantly higher for patients with age ≤50 years (AOR
conclusionsRTW of more than 180 WNDs was associated with younger age, early development of metastases and limited comorbidities during the year before the diagnosis of mBC. Patients diagnosed with mBC in 2003 or later had more WNDs and better survival than those diagnosed earlier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.